PCNU, a N-(2-chloroethyl)-N-nitrosourea, was administered to 37 previously treated patients with metastatic adenocarcinoma of the colon and rectum. The drug dose was 100 mg/m2, intravenously, over one hour for good risk patients and 75 mg/m2 for poor risk patients. Poor risk patients were defined as patients over 65 years of age or having liver enzymes greater than twice normal. The infusion was repeated at 6 week intervals. Seventeen patients (median performance status 80%) received PCNU at the 100 mg/m2 dose; 20 patients (median performance status 70%) received PCNU at the 75 mg/m2 dose. Complete responses were not observed. One patient treated with 100 mg/m2 achieved a partial response. Toxicity was primarily hematological with life-threatening leukopenia and thrombocytopenia observed in six patients. PCNU administered in the described dose schedule demonstrated little therapeutic efficacy in this patient population.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
MacDonald JS: Chemotherapy in the management of gastrointestinal cancer. Abdom Sur 21:126–131, 1979
Moertel CG: Chemotherapy of gastrointestinal cancer. New Eng J Med 299:1049–1052, 1978
Lokich JJ: Change to infusion chemotherapy for cancer. Curr Concepts Oncol 6:3, 1984
Seifert P, Baker LH, Reed M: Comparison of continuously infused 5-fluorouracil with bolus injection in the treatment of patients with colorectal adenocarcinoma. Cancer 36: 123–128, 1975
Decker DA, Samson MK, Baker LH: PCNU in advanced adenocarcinoma of the ovary. A Phase II study. Cancer Treat Rep 67:511–512, 1983
Dimery LW, Legha SS, Murphy WK: Phase II study of PCNU in the treatment of head and neck carcinoma. Cancer Treat Rep 68:437–438, 1984
Harvey JH, Smith FP, Bowers MW: Phase II trial of PCNU in advanced renal cell carcinoma and malignant melanoma. Cancer Treat Rep 68:1049–1050
Hancock C, Alien J, Tan CT: Phase II trial of PCNU in children with recurrent brain tumors and Hodgkin's disease. Cancer Treat Rep 68:441–442, 1984
Kalman LA, Gralla RJ, Casper ES: Phase I trial of PCNU. Cancer Treat Rep 67:1027–1028
Kalman LA, Stoopler MB, Casper ES: Phase II trial of PCNU in non-small cell lung cancer. Cancer Treat Rep 67:837, 1983
Levin VA, Resser KJ, McGrath L: PCNU treatment for recurrent malignant gliomas. Cancer Treat Rep 68:969–973, 1984
Martino S, Samal BA, Singhakowinta A: PCNU in advanced breast cancer. Cancer Treat Rep 67:305–306, 1983
About this article
Cite this article
Pazdur, R., Samson, M.K. & Baker, L.H. PCNU: Phase II evaluation in advanced colorectal carcinoma. Invest New Drugs 6, 93–95 (1988). https://doi.org/10.1007/BF00195366
- colon carcinoma
- rectal carcinoma
- colorectal carcinoma
- phase II